TScan Slashes 75% of Workforce, Pauses Phase 3 Trial, and Faces Nasdaq Delisting
TCRX is trading near its 52-week low of $0.656 (2.5% above the low).
Summary
TScan Therapeutics announced a 75% workforce reduction, paused its Phase 3 ALLOHA-2 trial due to capital constraints, and received a Nasdaq delisting notice for failing to maintain a $1.00 minimum bid price.
Key Events · Legal and Risk Events · TCRX
-
75% Workforce Reduction
As part of a strategic reorganization, TScan is cutting approximately 75% of its workforce, with expected employee-related costs of $4.1 million, primarily for pay continuation and benefits.
-
Phase 3 ALLOHA-2 Paused
Enrollment in the Phase 3 ALLOHA-2 study of TSC-101 is paused due to insufficient capital, with 7 patients already enrolled on the treatment arm continuing to be followed.
-
Nasdaq Delisting Notice
Nasdaq notified TScan on August 27, 2026, that its stock failed to maintain the $1.00 minimum bid price for 30 consecutive trading days, with a compliance deadline of February 23, 2027.
-
CFO and CMO Terminated
CFO Jason Amello and CMO Chrystal Louis were terminated effective September 2, 2026, with CEO Gavin MacBeath assuming principal financial and accounting officer duties.
Analysis · TCRX · Life Sciences
A sweeping strategic reorganization at TScan Therapeutics cuts 75% of its workforce, pauses enrollment in its Phase 3 ALLOHA-2 study of TSC-101 due to insufficient capital, and shifts focus to its preclinical in vivo solid tumor program. The company also received a Nasdaq notice on August 27, 2026, for failing to maintain a $1.00 minimum bid price, with a compliance deadline of February 23, 2027. CFO Jason Amello and CMO Chrystal Louis were terminated effective September 2, 2026, and CEO Gavin MacBeath assumed their financial duties. The restructuring is expected to cost $4.1 million in employee-related charges but generate $55.0 million in cumulative savings through 2027, extending the cash runway into Q4 2027. This filing confirms the going-concern warning from the August 12, 2026 10-Q and the loss of the Amgen collaboration on August 18, 2026, which eliminated over $500 million in potential milestone payments. The stock trades at $0.672, near its 52-week low of $0.6556, and the company must regain compliance with Nasdaq's minimum bid price rule or face delisting.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 42% of the 419 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TCRX was trading at $0.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $45.2M. The 52-week trading range was $0.66 to $2.57. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.